Skip to main content
. 2022 Sep 27;7(3):208–219. doi: 10.3138/jammi-2022-0013

Table 1:

Baseline characteristics of patients with COVID-19 including those responding and not responding to follow-up invitation

Demographics No. (%) of patients*
All patients; n = 993 Seen at 90-day follow-up; n = 206 Declined follow-up invitation; n = 260 Never responded to follow-up; n = 506 Died prior to 90 days; n = 21
Age (median, IQR) 38 (27-57) 51 (35–61) 37 (26–54) 34 (25–53) 79 (71–88)
Sex (female) 514 (51.7) 122 (59.2) 136 (52.3) 246 (48.6) 10 (43.5)
Pregnant 20 (2.0) 7 (3.4) 5 (1.9) 8 (1.6) 0 (0)
Health care worker 206 (20.7) 66 (32.0) 57 (21.9) 83 (16.4) 0 (0)
International travel (within 14 days of symptom onset) 73 (7.3) 21 (10.2) 15 (5.7) 36 (7.1) 1 (4.4)
Known exposure to case with COVID-19 524 (52.7) 96 (46.6) 140 (53.8) 272 (53.8) 16 (69.6)
Household contacts (average per case) 0.9 0.9 0.9 0.9 0.8
Number of days from symptom onset to COVID-19 test 4.2 (-5 to 42) 4.4 (-3 to 37) 4 (-1 to 31) 4.4 (-4 to 42) 3.1 (-5 to 11)
Location of COVID-19 test
    Assessment centre 707 (71.1) 106 (51.4) 189 (72.7) 411 (81.2) 1 (4.4)
    In-hospital 219 (22.0) 80 (38.8) 60 (23.0) 62 (12.3) 17 (73.9)
Number of days from symptom onset to initial COVIDEO assessment 6.5 (-2 to 48) 7 (-2 to 48) 6.5 (1 to 46) 6.3 (-2 to 44) 5.2 (2 to 17)
Initial symptoms grouped by system
    Constitutional 629 (63.2) 151 (73.3) 159 (61.2) 302 (59.7) 17 (73.1)
    Cardiorespiratory 557 (56.0) 134 (65.1) 148 (57.0) 257 (50.8) 18 (78.3)
    Upper respiratory 468 (47.0) 103 (50.0) 112 (43.1) 250 (49.4) 3 (13.0)
    Neurological 527 (53.0) 121 (58.7) 141 (54.2) 255 (50.4) 10 (43.5)
    Gastrointestinal 296 (29.8) 80 (38.8) 77 (29.6) 134 (26.5) 5 (21.7)
    Rheumatologic 373 (37.5) 96 (46.6) 103 (39.6) 173 (34.2) 1 (4.4)
    Psychiatric 290 (29.2) 79 (38.4) 76 (29.2) 133 (25.3) 7 (30.4)
Comorbidities
    Cardiac disease 66 (6.6) 14 (6.8) 19 (7.3) 25 (4.9) 8 (34.8)
    Hypertension 176 (17.6) 57 (27.7) 45 (17.3) 61 (12.1) 13 (56.5)
    Diabetes 93 (9.3) 22 (10.7) 21 (8.1) 42 (8.3) 8 (34.8)
    Chronic lung disease 29 (2.9) 8 (3.9) 4 (1.5) 10 (2.0) 7 (30.4)
    Asthma 89 (8.9) 27 (13.1) 22 (8.4) 38 (7.5) 2 (8.7)
    Chronic kidney disease 29 (2.9) 5 (2.4) 9 (3.5) 11 (2.2) 4 (17.4)
    Chronic liver disease 11 (1.1) 2 (0.9) 4 (1.5) 4 (0.8) 1 (4.4)
    Malignancy 62 (6.2) 14 (6.8) 19 (7.3) 20 (4.0) 9 (39.1)
    Chronic hematologic disease 23 (2.3) 6 (2.9) 4 (1.5) 11 (2.2) 2 (8.7)
    Rheumatic disease 17 (1.7) 7 (3.4) 5 (1.9) 3 (0.6) 2 (8.7)
    HIV 4 (0.4) 0 (0) 2 (0.8) 1 (0.2) 1 (4.6)
    Chronic neurological disease 60 (6.0) 9 (4.3) 16 (6.2) 21 (4.2) 14 (60.9)
    Obesity 49 (4.9) 22 (10.7) 15 (5.8) 12 (2.4) 0 (0)
    Smoker 66 (6.6) 13 (6.3) 22 (8.4) 29 (5.7) 2 (8.7)
    Malnutrition 8 (0.8) 0 (0) 1 (0.4) 3 (0.6) 4 (17.4)
Antibiotic therapy
    Beta-lactam 96 (9.7) 28 (13.6) 31 (11.9) 24 (4.7) 13 (56.5)
    Macrolides 55 (5.5) 17 (8.3) 19 (7.3) 14 (2.8) 5 (21.7)
Additional household cases 0.8 (0–6) 0.8 (0–6) - - -
Lymphocyte count 1.2 (0.5) 1.2 (0.2–3.3) 1.1 (0–2.4) 1.3 (0.3–5.0) 1.2 (0.4–4.3)
Abnormal chest X-ray 171 (17.1) 59 (28.6) 45 (17.3) 49 (9.7) 18 (78.3)
Hospitalization at or within 30 days of diagnosis 145 (14.5) 44 (21.4) 46 (17.7) 35 (6.9) 20 (87.0)
Days from diagnosis to hospital admission 1.4 (-61 to 74) 2 (-3 to 11) 3 (-31 to 74) 0.9 (-61 to 70) -2.5 (-34 to 6)
ICU admission within 30 days of diagnosis 44 (4.4) 15 (7.3) 13 (5.0) 9 (1.8) 7 (30.4)
Mechanical ventilation within 30 days of diagnosis 34 (3.4) 11 (5.3) 9 (3.5) 7 (1.4) 7 (30.4)
Duration of hospitalization, d 1.7 (0–164) 1.7 (0–23) 1.6 (0–125) 1.0 (0–164) 17.8 (0–61)
Duration of mechanical ventilation, d 6.7 (0–60) 4.8 (0–21) 5.8 (0–60) 8.5 (0–36) 9.5 (0–52)

*Unless otherwise specified